Plasma Omentin Levels Research Articles

The Relationship between Omentin Gene (ITLN1) Variant rs190234680 and Serum Omentin levels in patients with Diabetic Foot

Diabetic foot is a common and serious complication of diabetes, characterized by neuropathy, ischemia, and infections which can lead to amputation of the affected limb. Omentin is a protein that is predominantly expressed in adipose tissue and has been implicated in insulin sensitivity and glucose metabolism. Low plasma omentin levels have been associated with several metabolic disorders, including T2DM. Objectives: Study objective were to assess the pattern of omentin-1 [ITLN1] single nucleotide gene polymorphism in diabetic foot patients compared to uncomplicated T2DM. It also sought to compare the serum omentin-1 levels between diabetic foot patients and those with uncomplicated Type 2 diabetes mellitus and determine the association between omentin levels and the clinical staging of diabetic foot patients. Methodology: In this cross-sectional analytical study, 130 participants of DF and T2DM were enrolled. Omentin (ITLN1) gene polymorphism(rs190234680) was determined by sequencing and serum omentin levels were estimated by ELISA. Result: A significant association was observed between the GG genotype (wild type) of the omentin (ITLN1) gene and diabetic foot, while no significant difference was found in serum omentin levels between cases and controls. The analysis did not provide clear evidence of a significant relationship between omentin levels in different grades of diabetic foot Conclusion:The study suggested that the GG genotype of omentin 1 gene may be an important risk factor in development of diabetic foot in patients with type 2 diabetes. However, there was no significant difference in serum omentin levels between different stages of diabetic foot.

Omentin-1 Levels and Outcomes in Incident Peritoneal Dialysis Patients

Omentin-1 is an adipokine with anti-inflammatory and cardioprotective properties. The objective of this study was to determine the prognostic role of plasma omentin-1 levels in incident peritoneal dialysis (PD) patients. Retrospective analysis of prospective cohort. 152 incident PD patients. Plasma omentin-1 level, adipose tissue omentin-1 messenger RNA (mRNA) expression. Patient survival, technique survival, hospital admission, and duration of stay. Time-to-event survival analyses; linear regression for hospitalization. The mean age was 58.4±11.7 years; 102 were men, and 92 had diabetes. There was no significant correlation between plasma omentin-1 level and its adipose tissue mRNA expression. A higher plasma omentin-1 level quartile was not associated with patient survival (P=0.92) or technique survival (P=0.83) but had a modest correlation with a lower number of hospital admissions (P=0.07) and shorter duration of hospital stay (P=0.04). In adjusted models using multivariable linear regression, a higher plasma omentin-1 level quartile remained significantly associated with fewer hospital admissions (β, -0.13; 95% CI, -0.26 to -0.002; P=0.05) and shorter hospitalization duration (β, -0.20; 95% CI, -0.38 to -0.02; P=0.03). Observational study with baseline measures only. Plasma omentin-1 level was not associated with patient survival, technique survival, or peritonitis, but higher plasma omentin-1 levels were associated with fewer hospital admissions and shorter duration of hospitalization among incident PD patients.

PS-C05-12: OMENTIN-1 PREDICTS MEMBRANE FLUIDITY OF RED BLOOD CELLS AND MICROCIRCULATORY FUNCTION IN HYPERTENSIVE SUBJECTS BY THE NITRIC OXIDE-DEPENDENT MECHANISM

Objective: It has been shown that abnormalities in physical properties of the cell membranes may strongly be linked to hypertension. Recent evidence indicates that omentin-1, an adipokine with anti-inflammatory properties, may actively participate in the pathophysiology of hypertension, atherosclerosis and other cardiovascular diseases. However, few studies have evaluated the association between omentin-1 and membrane function in hypertension. The present study was performed to investigate possible relationships among omentin-1, endothelial function and membrane fluidity (a reciprocal value of membrane microviscosity) of red blood cells (RBCs) in patients with essential hypertension and normotensive subjects. Design and method: We measured the membrane fluidity of RBCs with an electron spin resonance (ESR) and spin labeling method. In each ESR spectrum, we calculated the order parameter (S) for the spin-label agent (5-nitroxide stearate). The greater the value of the order parameter (S) was, the lower the membrane fluidity of RBC was. Results: (1) The order parameter (S) obtained from the ESR spectra of RBC membranes was significantly greater in hypertensive subjects (0.727 ± 0.001, n = 64) than in normotensive subjects (0.719 ± 0.001, n = 49, P < 0.0001), indicating that membrane fluidity of RBCs might be reduced in hypertensive subjects compared with normotensive subjects. (2) Plasma omentin-1 levels were lower in hypertensive subjects than in normotensive subjects (HT 0.486 ± 0.014 ng/mL, n = 64, NT 0.537 ± 0.019 ng/mL, n = 49, P < 0.05). Plamsa omentin-1 significantly correlated with plasma nitric oxide (NO)-metabolite levels (an index of endothelial function) (r = 0.392, n = 113, P < 0.0001). (3) Furthermore, the order parameter (S) of RBCs inversely correlated with both plasma omentin-1 (r = -0.347, n = 113, P < 0.001) and plasma NO-metabolites, suggesting that reduced membrane fluidity of RBCs might be associated with decreased levels of plasma omentin-1 and endothelial dysfunction. (4) Multivariate regression analysis showed that, after adjusting for confounding factors, plasma omentin-1 might be an independent predictor of membrane fluidity of RBCs. Conclusions: The ESR study demonstrated that lower plasma omentin-1 levels might have a close correlation with reduced membrane fluidity of RBCs and impaired hemorheologic behavior in hypertensive subjects by the NO-dependent mechanism. It is strongly suggested that plasma omentin-1 could be a putative biomarker for the microcirculatory function in hypertension.

Omentin as an Independent Predictor of Metabolic Syndrome and Obesity Among Adolescents in Northeast China.

We investigated the association of omentin with metabolic syndrome (MetS), MetS components, and obesity in adolescents. A total of 742 middle-school students from Liaoyang City were enrolled in this cross-sectional study using the stratified cluster sampling method. Clinical information and blood samples were collected, and serum omentin levels were measured using enzyme-linked immunosorbent assay. Mean plasma omentin levels were lower in male than in female participants (88.25 (interquartile range 63.02-133.61) vs 99.46 (interquartile range 69.08-188.35) ng/L, P = 0.004). The participants were divided into four groups according to the quartile (Q) values of omentin from low to high. With increasing omentin levels from Q1 to Q4, the age of adolescents and the proportion of males gradually increased (P < 0.05), whereas the body mass index (BMI) (P < 0.05) and prevalence of MetS (P > 0.05) tended to decrease. Omentin levels were significantly and negatively correlated with waist circumference and BMI (correlation coefficients of -0.099 and -0.115, respectively). Regression analysis showed that omentin level was independently associated with the risk of MetS (Odds ratio, OR = 0.639, 95% confidence interval, CI (0.432, 0.945)), which was attributed to the association with central obesity (OR = 0.775, 95% CI (0.605, 0.993)) among MetS components. Increased omentin levels also indicated a reduced risk of obesity (OR = 0.700, 95% CI (0.563, 0.870)). Omentin is an independent predictor of MetS and obesity among adolescents in northeast China.

Association of plasma Omentin-1 and gestational diabetes mellitus in local population of Pakistan.

Objective: To determine plasma omentin-1 levels in pregnant females suffering from gestational diabetes mellitus. Study Design: Case Control study. Setting: Outpatient Department of Obstetrics and Gynecology, Tertiary Care Hospital of Karachi, Pakistan. Period: June 2021 to December 2021. Material &amp; Methods: Ninety-nine gestational diabetic and ninety-six healthy pregnant women were included in this study. A diagnostic criterion for gestational diabetes was oral glucose tolerance test between 24th to 28th weeks of pregnancy. ELISA was performed at KIBGE lab for estimation of plasma omentin-1 levels. Data was analyzed by SPSS software version 22. Results: Mean age of the patients was 30.8±6.4 years. GDM patients had increased BMI (36.0± 6.6vs 32.3 ±4.7; p=0.001), FBG (110 ±14 vs 77± 9; p=0.001), however, plasma omentin-1levels (4.90±9.01vs 9.56±12.11; p=0.001) were found reduced in GDM as compared to nGDM females. Statistically significant negative correlation was found between plasma omentin-1 and body mass index (BMI) (p=0.02). Simple and multi variable regression analysis revealed the statistically significant association of plasma omentin-1 with GDM. Conclusion: Our study has concluded that reduced plasma omentin-1 levels may play a significant role in the development of GDM during pregnancy, so it might be a new possible biomarker for early GDM diagnosis.

Relationship between plasma omentin-1 levels and newly diagnosed Stage I hypertension

Relationship between plasma omentin-1 levels and newly diagnosed Stage I hypertension

Association of Plasma Omentin-1 Levels With Diabetes and Its Complications.

Introduction: Plasma omentin-1 is a relatively new biomarker that has anti-diabetogenic and its level is inversely related with insulin resistance and diabetes mellitus, thus, increasing the risk of diabetic complications. In this study, we will determine the association between serum plasma omentin-1 levels and diabetes and its complications.Methods: This case control study was conducted from July 2020 to August 2021 in the internal medicine unit of a tertiary care hospital in Pakistan. There was a total of three groups, each comprising 250 patients. One group was type 2 diabetic patients with complications, the second group was type 2 diabetic patients without complications, and the third group was the control group, i.e. participants without type 2 diabetes. Their plasma omentin-1 levels were compared.Results: Patients with diabetic complications had significantly lower serum omentin levels than patients without complications (59.01 ± 9.21 ug/dL vs. 75.72 ± 14.11 ug/L; p-value: <0.0001). Patients with diabetes had significantly lower serum omentin levels in comparison to patients without diabetes (75.72 ± 14.11 ug/dL vs. 90.12 ± 17.89 ug/L; p-value: <0.0001).Conclusion: Based on our study, plasma omentin-1 is negatively associated with diabetes and its complications. Therefore, adequate levels of omentin-1 are needed in order to prevent diabetic complications.

Association Between Coronary Artery Disease and Plasma Omentin-1 Levels.

Introduction: Omentin-1 is secreted from visceral adipose tissue that contributes to chronic inflammatory diseases’ pathogenesis, including cardiovascular events. In this case-control study, we will determine the association between plasma omentin and coronary artery disease (CAD).Methods: This is a case-control study, conducted from June 2020 to April 2021 in the cardiology unit of a tertiary care hospital in Pakistan. Patients diagnosed with CAD (n = 300) within the last six months were included in the study. Another 300 participants without CAD and with similar demographic profiles were included in the control group. A blood sample of 5 ml was drawn from participants of both groups and sent to the laboratory to test for plasma omentin level.Results: Plasma omentin level was significantly lower in patients with CAD compared to the patients without CAD (61.21 ± 10.21 ng/dL vs. 95.22 ± 12.21 ug/L; p-value: <0.0001). In both genders, the plasma omentin-1 was lower in patients with CAD compared to patients without CAD (p-value: <0.0001).Conclusion: The present study revealed a negative association between omentin-1 and CAD. We speculate that low levels of omentin-1 might play a role in the pathogenesis of atherosclerosis. Therefore, plasma omentin-1 can be a potential biomarker to predict the development and progression of CAD.

Evaluation of omentin levels in patients with unstable angina pectoris, non-ST elevated myocardial infarction (NSTEMI) and STEMI

Aim: Acute coronary syndrome (ACS) is an ischemic cardiac disease that could result in myocardial necrosis with prolonged ischemia. Omentin (intelectin-1) is a new biomarker that is released from adipose tissue. It is associated with coronary artery disease (CAD) and has an acute ischemic injury-reducing effect. This study aimed to assess the omentin levels in patients with unstable angina pectoris (USAP), Non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevated myocardial infarction (STEMI). Methods: This case-control prospective study included 59 patients with ACS and 22 healthy subjects. MB fraction of creatine kinase (CKMB), troponin, myoglobin, and omentin levels were measured from venous blood obtained from each patient within six hours after the onset of symptoms. Plasma omentin levels were determined with an omentin enzyme-linked immunosorbent assay kit. Results: The patient group was older than the control group (P 0.05). The rate of smoking was higher in the patient group, and the patient group was heavier than the control group (P>0.05). Omentin levels were similar in ACS patients and control subjects (6.0 (1.7) vs. 6.3 (1.3), P=0.40). There was no significant correlation among CKMB, troponin, myoglobin, and omentin levels. Moreover, omentin levels were similar in ACS subgroups (P=0.58). There was no significant correlation between body mass index and omentin levels (r =-0.186, P=0.09). Conclusion: This study revealed that there was no significant relationship between omentin and myoglobin levels in ACS patients. The potential usefulness of blood concentrations of omentin levels in understanding the relationship with ACS warrants further studies.

Analysis of the expression of plasma omentin-1 level in colorectal cancer and its correlation with prognosis.

BackgroundColorectal cancer (CRC) is a malignant tumor of the digestive tract, with high incidence and mortality. This study aims to investigate the expression of plasma omentin-1 level in patients with CRC and its correlation with the prognosis of patients.MethodsClinical data of 319 patients (case group) who underwent radical resection of CRC in our hospital from June 2015 to March 2018 were collected, simultaneously, 300 people without the apparent physical disease who underwent physical examination in our hospital during the same period were randomly selected as the control group, plasma omentin-1 levels in the two groups were compared by T-test. Cancer patients were followed up, and multi-factor COX regression analysis was used to analyze the factors affecting patients’ recurrence and survival.ResultsThe level of plasma omentin-1 in patients with colorectal cancer is closely related to TNM staging and lymph node metastasis. The CRC case group was significantly reduced after surgery, but it was still higher than that in the control group (P<0.05). At the end of the follow-up, 28 cases were lost to follow-up, and 291 cases (91.22%) were effectively followed up. During the follow-up period, the recurrence and metastasis rate was 30.58% (89/291), and the mortality rate was 19.26% (56/291). According to the multi-factor analysis, the risk factors for the recurrence of CRC patients were TNM stage III–IV (OR =1.978, 95% CI: 1.088-3.596), lymph node metastasis (OR =2.073, 95% CI: 1.179–3.645) and omentin-1 level ≥50 ng/mL (OR =3.347, 95% CI: 1.416–7.912). The risk factors for the survival of patients with CRC were poorly differentiated (OR =1.960, 95% CI: 0.985–3.900), lymph node metastasis (OR =2.452, 95% CI: 1.213–4.956), vascular carcinoma thrombus (OR =2.026, 95% CI: 1.036–3.960) and omentin-1 level ≥50 ng/mL (OR =2.067, 95% CI: 1.013–4.218).ConclusionsThe level of plasma omentin-1 is highly expressed in patients with CRC, an independent risk factor for the recurrence and survival of patients.

Circulating omentin-1 levels and inflammation in polycystic ovary syndrome.

The aim of the study was to analyze interrelation between plasma omentin-1 levels and nutritional status and inflammation in PCOS. A cross-sectional study involving 86 PCOS (47 obese) and 72 Non-PCOS women (41 obese) determined anthropometric parameters and body composition. Serum glucose, insulin and omentin-1, TNF-α, sTNFRs, IL-6 and sR-IL6 were measured in the fasting state. Plasma omentin-1 levels were significantly lower in the PCOS than in the Non-PCOS group and both corresponding normal weight and obese subgroups. In three analyzed least-angle regression (LARS) models the lower plasma omentin- 1 levels was associated with PCOS occurrence, higher circulating TNF-α and lower IL-6 levels. Suppressed omentin-1 levels in PCOS are characteristic for this disturbance and proinflammatory cytokines are factors modifying secretion of this adipokine.

Clinical relevance of serum omentin-1 levels as a biomarker of prognosis in patients with acute cerebral infarction.

Background and purposePrevious studies have shown that adipocytokines are associated with atherosclerosis, diagnosis, and functional prognosis after ischemic stroke. However, few studies have investigated the relationship between omentin‐1 and atherosclerotic acute cerebral infarction (ACI).MethodsIn this study, we investigated the association between serum omentin‐1 levels at admission and severity, infarction volume, and functional prognosis of patients 90 days after atherosclerotic ACI.ResultsA total of 109 patients with atherosclerotic ACI were enrolled. Serum omentin‐1 levels at admission were lower in patients with ACI than those in healthy controls (47.18 ± 13.64 vs. 56.27 ± 34.44 ng/ml, p = .014). Serum omentin‐1 levels at admission were negatively correlated with severity of ACI (r = −.271, p = .004) and infarction volume (r = −.264, p = .006), respectively. Moreover, serum omentin‐1 levels were lower in the poor functional prognosis group than those in the good functional prognosis group in patients with large artery and small artery atherosclerotic ACI. In a logistic regression analysis, higher serum omentin‐1 level (>43.10 ng/ml) at admission was negatively associated with a poor functional prognosis 90 days after atherosclerotic ACI.ConclusionsSerum omentin‐1 levels at admission were significantly lower among patients with ACI. A higher plasma omentin‐1 level (>43.10 ng/ml) was negatively associated with poor functional prognosis 90 days after atherosclerotic ACI. Further studies are needed to investigate the pathophysiological mechanism of omentin‐1 in affecting attacks and prognosis of ACI as well as to confirm the value of plasma omentin‐1 level as a potential biomarker.

MON-691 Association of Serum Level of Omentin-1, Hs-CRP and Atherosclerosis in Patients with Type 2 Diabetes

Omentin-1 has been identified as an interesting novel adipokine that may modulate the action of insulin. Serum omentin-1 levels were associated with endothelial dysfunction and cardiovascular diseases, which highly contribute to morbidity and mortality of patients with diabetes, however its exact biological function is still unclear. The aim of this study was to assess the level of circulating plasma Omentin-1 level in patients with type 2 diabetes compared to control subjects, and to investigate the relationship of circulating Omentin-1levels with HOMA, BMI, lipid profile, epicardial fat, visceral fat and subcutaneous fat in early stages of atherosclerosis measured by carotid intima media thickness (CIMT). This is a cross-sectional observational study which included 45 patients with type 2 DM (not previously diagnosed as ACVD patients) and 30 (age and sex)-matched healthy control subjects. Patients with a history of recent acute infection, malignancy, metabolic or endocrinal diseases, cardiac failure, renal and hepatic impairment were excluded. Participants were subjected to measurement of FPG, HbA1c, lipid profile, calculation of HOMA2, hs CRP, serum omentin-1, CIMT, estimation of visceral, epicardial and subcutaneous fat through CAT scanning. There was no statistically significant difference between both groups in the mean circulating omentin-1 level, a mean of (793.86 ± 195.81) ng/ml in type 2 diabetes Vs (804.93 ± 205.76) ng/ml in the control group,(p=0.654). However, there was a highly statistically significant difference in hs-CRP between both groups, mean hs CRP is (4.29 ± 4.87 mg/l) vs (0.92 ± 0.53 mg/l) respectively. There was a statistically significant negative correlation between omentin-1 and hs CRP (r= -0.278, p= 0.016).There were no statistically significant correlations between omentin-1 with BMI, HbA1c, HOMA, lipid profile or adiposity. These findings may denote the anti-inflammatory effects of omentin-1 which maybe unrelated to insulin resistance and dyslipidemia. Further studies are required to confirm the cardioprotective role of omentin-1 in patients with type 2 diabetes, focusing on its local anti-inflammatory role.Nothing to disclose: MA, NA, NKNo Sources of Research Support

Association of omentin-1, adiponectin, and resistin genetic polymorphisms with systemic lupus erythematosus in a Chinese population

ObjectiveAn increasing number of studies have demonstrated the roles of adipokines in systemic lupus erythematosus (SLE). We aimed to investigate the association of genetic variations of omentin-1, adiponectin, and resistin with SLE susceptibility. MethodsWe selected 623 SLE patients and 665 normal controls in the present study. Genotyping of omentin-1 rs2274907, rs35779394, rs79209815, and rs13376023; adiponectin rs16861194 and rs266729; and resistin rs1862513, rs3745368, and rs3745367 was conducted by TaqMan SNP genotyping assays. ResultsOverall, we found no significant differences in the allele or genotype frequencies of the nine studied SNPs between the SLE patients and controls. However, an increased frequency of the resistin rs3745368 variant was observed in the SLE patients under the dominant model (P = 0.024). In omentin-1, the rs13376023 A allele was found to be related to oral ulcers in SLE patients (P = 0.013), and the rs35779394 C and rs13376023 A allele frequencies were significantly lower in SLE patients with BMI ≥ 24 kg/m2 (P = 0.019, P = 0.033, respectively). For resistin, the frequencies of the rs3745368 AA genotype and A allele were lower in SLE patients with discoid rash (P = 0.036, P = 0.011), and the rs3745368 A allele frequency was higher in SLE patients with lupus nephritis (P = 0.018). The resistin rs3745367 AA genotype and A allele frequencies were related to the occurrence of renal disorder in SLE patients (P = 0.024, P = 0.009). The haplotype analysis showed that the CGA haplotype of resistin was associated with susceptibility to SLE (P = 0.005). No significant associations of plasma omentin-1, adiponectin or resistin levels with their respective genotypes were found in SLE patients. ConclusionsIn summary, omentin-1, adiponectin and resistin SNPs are not associated with the genetic background of SLE in Chinese patients. However, omentin-1 and resistin genetic variations might contribute to several clinical phenotypes of SLE.

Plasma omentin levels are inversely associated with atherosclerosis in type 2 diabetes patients with increased plasma adiponectin levels: a cross-sectional study

BackgroundOmentin and adiponectin are among the anti-inflammatory and anti-atherogenic adipokines that have potentially beneficial effects on cardiovascular disorders. Recent studies indicate a paradoxical relationship between adiponectin and cardiovascular mortality across many clinical settings including type 2 diabetes. In this study, we characterized the clinical features of type 2 diabetes patients with increased adiponectin levels and examined the association between omentin and atherosclerosis in those patients.MethodsThe subjects were 413 patients with type 2 diabetes. Fasting plasma omentin and total adiponectin levels were measured by enzyme-linked immunosorbent assay. The intima-media thickness (IMT) of the common carotid artery was measured by ultrasonography. The subjects were stratified according to the median value of plasma adiponectin.ResultsIn high-adiponectin group, omentin levels were higher, while IMT tended to be greater than those in low-adiponectin group. The high-adiponectin group also exhibited older age, higher systolic blood pressure, lower kidney function, body mass index, and insulin resistance index compared to the low-adiponectin group. Multivariate analysis revealed that omentin levels were independently and negatively associated with IMT in high-adiponectin group, but not in low-adiponectin group, after adjusting for adiponectin levels and traditional cardiovascular risk factors. On the other hand, adiponectin levels were not significantly associated with IMT in either group.ConclusionsPlasma omentin levels are inversely associated with IMT in type 2 diabetes patients with increased adiponectin levels and multiple cardiovascular risk factors. This study suggests a protective role of omentin against atherosclerosis in type 2 diabetes patients, which is potentially influenced by adiponectin level and cardiovascular risk status.

Effect of insulin\u2013glucose metabolism compared with obesity on adipose omentin gene expression in different models of diabetic C57BL/6 mice

BackgroundOmentin, releasing by adipose-tissue may be related to glucose metabolism. The omentin circulating levels and the related mRNA expression in visceral adipose-tissue are different in types of diabetes and the exact function of this molecule is still unknown. The aim of this study was to examine omentin gene expression in adipose-tissues of type-1 and type-2 diabetic mice for the investigation of the effects of fat-mass and insulin–glucose metabolism.MethodsIn this study, 36 C57BL/6 mice were divided into four experimental groups, including control, type-1 diabetes (inducted by streptozotocin), type-2 diabetes with obesity (high-fat diet + low-dose-streptozotocin [HFD + STZ]), and type-2 with normal weight (normal-pellet diet + low-dose-streptozotocin [NPD + STZ]). The present study involved the measurements of oral-glucose-tolerance-test and the levels of biochemical parameters, including blood glucose, omentin, insulin, lipid-profile, as well as aminotransferases. In addition, the omentin mRNA expression was evaluated by real-time polymerase-chain-reaction.ResultsThe results of omentin gene expression analysis showed a significant difference between mRNA expressions in the experimental groups. The plasma omentin levels were significantly higher in type-1 diabetes group and lower in type-2 diabetes with NPD + STZ; however, the plasma omentin levels were not changed in the HFD + STZ group. In addition, the findings of serum-biochemical analysis revealed significant differences, compared to the control-group.ConclusionsThe omentin expression may be affected by insulin and glucose levels in different types of diabetes more than fat-mass, and due to the local activity, the serum omentin may not comply with its gene expression.

Association between plasma omentin-1 levels in type 2 diabetic patients and peripheral artery disease

BackgroundType-2 diabetes mellitus is one of the major risk factors of atherosclerosis, particularly in peripheral artery disease (PAD). Several studies have documented a correlation between omentin-1 serum levels, atherosclerosis, and cardiovascular diseases. However, a clear link between circulating omentin-1 and PAD in diabetic patients has yet to be established. The aim of this study was to investigate the potential role of omentin-1 in PAD in type-2 diabetic patients.MethodsIn this cross-sectional study, we analyzed omentin-1 serum levels by ELISA in 600 type-2 diabetic patients with (n = 300) and without (n = 300) PAD at Fontaine’s stage II, III, or IV.ResultsWe found that omentin-1 serum levels were significantly lower in diabetic patients with PAD than in diabetic controls (29.46 vs 49.24 ng/mL, P < 0.001) and that the levels gradually decreased in proportion to disease severity (P < 0.05). The association between omentin-1 levels and PAD remained significant after adjusting for major risk factors in a multivariate analysis.ConclusionsOur results suggest that omentin-1 is reduced in type 2 diabetic patients with PAD and that omentin-1 levels are related to disease severity.

408-P: Plasma Omentin Levels Are Inversely Associated with Atherosclerosis in Type 2 Diabetes Patients with Elevated Plasma Adiponectin Levels

Omentin is an adipokine expressed in visceral adipose tissue and has beneficial effects on insulin action and cardiovascular system, like adiponectin. Recent evidence indicates a paradoxical relationship between high adiponectin levels and mortality across many clinical conditions including type 2 diabetes (T2D) and cardiovascular diseases (CVDs). In this study, we characterized clinical features of T2D patients with elevated adiponectin levels and examined the association between plasma omentin levels and atherosclerosis in those patients. Subjects were 413 patients with T2D. Fasting plasma omentin levels and total adiponectin levels were measured by ELISA, and the mean intima media thickness (IMT) of the common carotid artery was measured by ultrasonography. The medians of plasma omentin levels, adiponectin levels, and IMT were 573 ng/mL, 6.2 µg/mL, and 0.81 mm, respectively. In patients with higher adiponectin levels above the median (high-ADN), IMT tended to be greater, and omentin levels were higher than those in the low-ADN group. The high-ADN group also had older age, higher systolic BP, lower eGFR, BMI, HOMA-R, and HbA1c than the low-ADN group. Interaction analysis indicated an effect modification by adiponectin levels on the association between omentin levels and IMT. Stratified analysis by adiponectin level revealed that omentin levels were independently and negatively associated with IMT in the high-ADN group (β = -0.170, p = 0.022), but not in the low-ADN group, after adjusting for adiponectin levels and CVD risk factors. On the other hand, adiponectin levels were not significantly associated with IMT in either group. These data indicate that the high-ADN group in T2D has multiple CVD risk factors, in whom omentin is inversely associated with IMT. This study suggests a protective role of omentin, rather than adiponectin, against atherosclerosis in T2D with elevated adiponectin levels and accumulated CVD risk factors. Disclosure M. Hatamori: None. T. Morioka: Research Support; Self; Eli Lilly and Company, Merck &amp; Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation, Sanofi K.K., Takeda Pharmaceutical Company Limited. Speaker's Bureau; Self; Astellas Pharma Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck &amp; Co., Inc., Novo Nordisk Inc., Roche Diagnostics K.K., Sanofi K.K., Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited. Other Relationship; Self; Ono Pharmaceutical Co., Ltd. M. Senda: None. Y. Kakutani: None. Y. Yamazaki: None. K. Mori: Speaker's Bureau; Self; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd. S. Fukumoto: Research Support; Self; Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Kowa Pharmaceutical Europe Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited. Speaker's Bureau; Self; Novo Nordisk Inc., Sanofi K.K. A. Shioi: None. T. Shoji: Research Support; Self; Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd. Speaker's Bureau; Self; Kissei Pharmaceutical Co., Ltd., Kowa, Kyowa Hakko Kirin Co., Ltd. M. Emoto: Research Support; Self; Ono Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd. Speaker's Bureau; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Kowa Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sanofi, Sumitomo Dainippon Pharma Co., Ltd., Taisho Toyama Pharmaceutical CO., Ltd., Takeda Pharmaceutical Company Limited. M. Inaba: None.

Altered circulating levels of adipokine omentin-1 in patients with prostate cancer.

Background: Prostate cancer (PCa), one of the most common cancers in men, accounts for nearly 20% of adult malignant neoplasms. Omentin-1 is synthesized in visceral adipose tissue and its concentration in plasma changes with cancers. However, the association between omentin-1 and PCa was rarely studied. Thus, we investigated the plasma omentin-1 levels in PCa patients in Chinese population.Materials and methods: Ninety cases of PCa and 90 matched healthy controls were enrolled in this study. We used ELISA technique to determine the concentration of omentin-1.Results: The concentration of omentin-1 was higher in patients with PCa compared to controls (P<0.001). Additionally, positive correlations were uncovered between omentin-1 with body mass index (r=0.240, P=0.001), waist-hip ratio (r=0.228, P=0.002), and prostate-specific antigen (r=0.589, P<0.001). Receiver operating characteristic curve analysis indicated that plasma omentin-1 differentiated PCa patients from controls with a sensitivity of 85.9% and a specificity of 83.7%.Conclusion: Our study demonstrated that the levels of plasma omentin-1 were increased in PCa patients. Meanwhile, omentin-1 may be a possible biomarker for diagnosing PCa. For validation, more studies should focus on and elucidate the potential mechanism underlying this change.

Circulatory Omentin-1 levels but not genetic variants influence the pathophysiology of Type 2 diabetes

ObjectiveOmentin-1, an anti-inflammatory protein, is secreted by the visceral adipose tissue. Altered levels of Omentin-1 are associated with obesity and Type 2 Diabetes (T2D). Although Omentin-1 is implicated in the insulin signaling pathway, the relationship between the genetic variants of Omentin-1 and T2D is not yet explored. The current study evaluates the association of Omentin-1 polymorphisms (rs2274907 A/T and rs1333062 G/T), its transcript and protein levels, and genotype-phenotype correlation with metabolic parameters and T2D susceptibility. MethodsPlasma and Peripheral Blood Mononuclear Cells (PBMCs) were separated from venous blood taken from 250 controls and 250 T2D patients recruited from Gujarat, India. Genomic DNA was isolated from PBMCs and genotyping of Omentin-1 variants was performed by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP). RNA was isolated from Visceral Adipose Tissue (VAT) samples of 12 controls and 10 patients, and transcript levels of Omentin-1 were assessed by qPCR. Plasma Omentin-1 levels were estimated by ELISA. Fasting Blood Glucose, Body Mass Index (BMI) and plasma lipid profile were considered for the genotype-phenotype correlation analysis. ResultsOur study revealed no association of Omentin-1 genetic variants with T2D risk (p > 0.05). However, the AT genotype of Omentin-1 rs2274907 A/T polymorphism was associated with increased BMI (p = 0.0247). Plasma Omentin-1 levels were significantly decreased (p < 0.0001) however, increased VAT Omentin-1 transcript levels (p = 0.0127) were observed in T2D patients. ConclusionOur findings suggest that decreased circulatory Omentin-1 levels could pose a risk towards T2D susceptibility.